MedTrace Logo

Prasugrel With Lower Dose - Loading Dose

NCT02070159 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2014-02-25

No results posted yet for this study

Summary

Although prasugrel, recently available thienopyridine derivative, exhibits rapid and potent platelet inhibition, concerns of low on-treatment platelet reactivity have been suggested especially in East Asian ethnicities. The investigators compared the effect of lower loading dose of prasugrel with conventional loading dose of clopidogrel and prasugrel.

Conditions

Interventions

DRUG

Clopidogrel 600 mg

Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel

DRUG

Prasugrel 30 mg

Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.

DRUG

Prasugrel 60 mg

Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.

Sponsors & Collaborators

  • Dong-A University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-12-31
Completion
2013-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070159 on ClinicalTrials.gov